Bioinformatics study of anticancer activity for wild and mutant A۱۹K brazzein

Publish Year: 1399
نوع سند: مقاله کنفرانسی
زبان: English
View: 197

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

CIGS16_149

تاریخ نمایه سازی: 14 اردیبهشت 1400

Abstract:

Background and Aim: Anticancer peptides can be a useful and valuable factor in treating cancer. Brazzein protein can act as an anticancer peptide due to its specific structure and sequence. Toll-like receptors (TLRs) are innate immune receptors that are expressed in both of innate immune cells and various cancer cells and play a crucial role in the initiation and progression of cancers. According to previous researches, signaling of a TLR ۵ in human breast cancer has a strong anti-tumor activity.Methods: In this study, the molecular binding of both wild and mutant (A۱۹K) brazzein with TLR ۵ was investigated using the HADDOCK server.Results: The results suggest that brazzein could be a good candidate as an anticancer drug.Conclusion: according to docking, increasing the positive charge in the residue ۱۹ of brazzein increases its anti-cancer properties and improves the docking parameters compared to its wild type, and it seems that the mutation applied, plays an important role to bindings site of receptor. However, for confirmation, the results of this study require experimental studies.

Authors

Maede Poursalim

Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.

Vahab Jafarian

Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.

Elahe Karimipour

Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.